Hillstream BioPharma Announces Abstract at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting highlighting HSB-1216’s Effect in Triple Negative Breast Cancer (TNBC)
June 2nd, 2021
HSB-1216 and a novel anthracycline, pirarubicin, combined and targeted using Quatramer shows synergistic effect in TNBC
Bridgewater, NJ – June 2, 2021 – Hillstream BioPharma, Inc. (“Hillstream”) today announced that an abstract highlighting the progress of HSB-1216 pipeline candidate is being presented as an online publication only at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 4-8, 2021.
The accepted abstract, was released on May 19, 2021 at 5:00 pm EDT, summarizes non-clinical research in which HSB-1216 is being studied in combination with pirarubicin as dual drug-combination in an unexpected unique ratio in Quatramers for triple negative breast cancer (TNBC). “We are actively evaluating the potential utility of HSB-1216 in several solid tumor types,” stated Randy Milby, CEO of Hillstream. “We know that healthcare professionals and patients are hopeful about the role HSB-1216 therapy may play in treating these devastating cancers, and we are pleased to share our latest updates at this year’s ASCO meeting.”
The Hillstream sponsored Abstract No. e15047 is:
Co-loading of an anthracycline analogue Pirarubicin and Salinomycin in a 1:3 ratio into Quatramer biodegradable polymeric nanoparticles synergistically inhibit growth of triple-negative breast cancer.
The Hillstream BioPharma sponsored abstract will be published in the Journal of Clinical Oncology supplement to ASCO and will be accessible on the Hillstream website (www.hillstreambio.com).
Citation: J Clin Oncol 39, 2021 (suppl 15; abstract e15047)
HSB-1216, Hillstream’s lead compound, is a novel and potent inducer of an emerging anti-cancer mechanism, Iron-mediated Cell Death (IMCD). With iron’s central role in cell growth and metabolism, its dysregulation leads to cancer progression and metastasis. Cancer cells can rely on an increased labile iron pool (LIP) in the cytoplasm which fosters tumor growth and metastasis. HSB-1216 decreases the LIP in tumor cells by removing the excess free cytoplasmic iron used for uncontrolled and dysregulated. HSB-1216’s novel mechanism, IMCD also subsumes ferroptosis a novel regulated cell death pathway, which sequesters iron and leads to lysosomal membrane permeabilization of resistant cancer cells and cell death. Areas of interest for the development of HSB-1216 for the treatment of solid tumors, include triple negative breast cancer (TNBC) and other devastating and rare tumors.
About Hillstream BioPharma Inc.
Hillstream BioPharma Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death (“IMCD”) for drug resistant and devastating cancers. Our most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to be efficacious in a clinical pilot study in Germany in devastating cancers, including triple negative breast cancer (TNBC) and epithelial carcinomas. We intend to start a clinical study with HSB-1216 in 2022 to expand upon the existing early clinical proof-of-concept. We use Quatramer™, our proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment (“TME”) with an extended duration of action and minimal off-target toxicity. In addition, Trident Artificial Intelligence (“TAI” or “Trident”), our artificial intelligence precision medicine platform, is used to identify biomarkers in our clinical programs to target a specific patient segment most likely to benefit. For more information, please visit www.hillstreambio.com.
Forward Looking Statements
This press release includes forward-looking statements including, but not limited to, statements related to the development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management’s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.
Hillstream BioPharma Inc.
President & CEO
Hillstream Biopharma Inc.
Jennifer K. Zimmons, Ph.D.
Zimmons International Communications